机构:[1]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China[2]The First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China深圳市中医院深圳医学信息中心[3]Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China深圳市中医院深圳医学信息中心[4]Department of VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China[5]The Fourth School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China深圳市中医院深圳医学信息中心[6]Department of Oncology, The First Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, Guizhou 550000, China[7]Department of Obstetrics and Gynecology, Shenzhen University General Hospital Shenzhen, Guangdong 518000, China深圳大学总医院深圳市康宁医院深圳医学信息中心[8]Department of Oncology, Shenzhen Bao’an Authentic TCM Therapy Hospital, Shenzhen, Guangdong 518000, China深圳市康宁医院深圳医学信息中心[9]Department of Endocrinology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China大德路总院内分泌科大德路总院内分泌科广东省中医院[10]Post-Doctoral Research Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China广东省中医院[11]Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510120, China广东省中医院[12]The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China广东省中医院
This work was supported by the National Natural Science Foundation of China General Project: Based on the transformation of tumor-related macrophages to explore the mechanism of "Yiqi Chutan Prescription" against the invasion and metastasis of lung cancer (No. 82,074,382), and Guangdong Natural Science Foundation general project: To explore the effect of "Yiqi Chutan Formula" on the polarization of tumor-related macrophages from the TLR4/NF-κB signaling pathway (No. 2021A1515011232).
第一作者机构:[1]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China[2]The First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China
共同第一作者:
通讯作者:
通讯机构:[9]Department of Endocrinology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China[10]Post-Doctoral Research Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China[11]Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510120, China[12]The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China
推荐引用方式(GB/T 7714):
Zeng Zhili,Jiang Weichi,Kan Jun,et al.Shentao Ruangan formula promotes apoptosis via the E2F2-p53 pathway in hepatocellular carcinoma[J].PHYTOMEDICINE.2023,109:doi:10.1016/j.phymed.2022.154565.
APA:
Zeng Zhili,Jiang Weichi,Kan Jun,Zhang Dong,Li Rui...&Cao Zebiao.(2023).Shentao Ruangan formula promotes apoptosis via the E2F2-p53 pathway in hepatocellular carcinoma.PHYTOMEDICINE,109,
MLA:
Zeng Zhili,et al."Shentao Ruangan formula promotes apoptosis via the E2F2-p53 pathway in hepatocellular carcinoma".PHYTOMEDICINE 109.(2023)